The Bull Rankings scorecard — our quality-growth score is 77.1 / 100, built from three pillars scored 0–100: Quality 76, Growth 100, Value 60 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 52% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Credo is a compounder whose price, rich as it looks, still assumes its growth will cool sharply. In the quarter ended 2026-05-02, revenue exploded 205.7% year over year, yet shares still fell in after-hours trading after the print. The company’s profit margin sits at 35.4%, a figure most semiconductor names would kill for, and return on equity clocks in at 22.9%—both figures that anchor the quality-growth score of 77.1/100 our model assigns. The weakest pillar, Value, scores 60, still on the cheap side of peers for a business that prints cash while growing revenue at a blistering pace.
The market’s skepticism is understandable. A beta of 3.2 means this stock moves like a rocket on the way up and a boulder on the way down, and a PEG ratio of 0.39 says the multiple is modest for the earnings growth analysts expect. But the numbers don’t lie: Credo isn’t just growing—it’s compounding, and the sell-off in late July looks like panic over a misunderstood inflection.
What the business actually is
Credo sells the plumbing of the AI era. Its ZeroFlap (ZF) active electrical cables and ZF optical transceivers move data at blistering speeds for hyperscale data centers and AI clusters. The company also pushes OmniConnect memory solutions, which solve the bottleneck between CPUs and accelerators, and a suite of retimers and DSPs that keep signals clean across optical and copper Ethernet and PCIe. For customers who want to build their own chips, Credo licenses SerDes IP, turning its silicon into a foundry-style revenue stream. Every product line feeds the same beast: faster, denser, lower-power connectivity for the machines that now run the world.
Why it can (or can't) keep compounding
The durability case rests on two pillars: returns and moat. A 22.9% ROE means capital is deployed at a premium, and the 35.4% profit margin proves the business doesn’t need scale to be efficient—it’s already there. The moat is the SerDes IP and retimer ecosystem, which customers embed into their designs. Once a hyperscaler locks in Credo’s silicon, switching costs rise with every line of code and every rack of servers. Competitors can try to replicate the tech, but they can’t replicate the installed base of designs already shipping.
Our model flags one caution: diluting shareholders. The signal is real. If dilution accelerates, the compounding math breaks. For now, the growth engine hums, and the moat deepens with every new design win.
The valuation question
The market has priced in a lot, though less than the business just delivered. Our reverse DCF says today’s $201.08 share price implies 52% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten). That’s optimistic, even if well below recent growth. Actual revenue grew 205.7% in the latest fiscal year, but that’s a one-time surge from AI infrastructure buildout, not a sustainable 200% clip. The P/E of 80.4 and PS of 28.1 already assume Credo’s edge is permanent, its customers locked in forever, and its technology the only game in town.
A price implying 52% annual free‑cash‑flow growth is demanding by any measure, even against a revenue year that grew faster still. The bear case isn’t that Credo fails—it’s that the market’s assumption of 50%+ FCF growth next year collapses when AI capex growth slows.
The bear case
The strongest skeptic’s argument is simple: beta is 3.2. This stock doesn’t gently correct—it crashes. In late July, shares fell after a quarter that beat expectations, proving that good news no longer moves the needle. The market is telling Credo: Prove the growth is repeatable, or we’re walking. A single quarter of deceleration would shatter the narrative, and the stock would follow.
What would change our mind
Three numbers would flip the thesis. First, revenue growth below 100% year over year—a sign the AI buildout is maturing and Credo’s edge is fading. Second, ROE dipping below 20%—proof the capital isn’t compounding as efficiently. Third, dilution accelerating beyond current levels—a red flag that the growth story is being bought with equity, not earnings.
Until then, the market’s skepticism looks overdone. Credo’s fundamentals are strong. The valuation is demanding. The stock is volatile. But the compounding machine is real.